ValiRx gives NHS Long Term Plan its seal of approval

The AIM-traded firm said its stated ambition, for some time, had been the “personalisation” of novel therapeutics and through genetic mapping, to facilitate the early detection of cancers.

It said that ambition had long been at the forefront of much of its work in the oncology arena, saying it was “excellent news” that Westminster was now actively discussing and championing such therapeutic and diagnostic approaches.

With ValiRx currently developing precision therapeutics for hormone induced cancers, coupled with new technology for early detection, the company said it was “delighted” to be among the front runners contributing to the government and NHS-led initiative.

“ValiRx is an innovative biotechnology company developing novel and improved therapeutics, both in the UK and globally,” said chief executive officer Dr Satu Vainikka.

“The Government's recently announced ten-year plan of investing in the prevention and early diagnosis of diseases, such as certain neurological, mental and oncological diseases, is a policy that we have been following and striving to address for some time.”